Royalty Pharma plc
RPRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RPRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RPRX
Royalty Pharma plc is a leading royalty acquisition company that funds innovation in the biopharmaceutical industry by acquiring existing royalties and co-funding late-stage clinical trials, generating revenue from top-line sales of approved therapies.
Key risk: High debt level
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 29 clinical trials · 4 catalysts for Royalty Pharma plc.
Royalty Pharma plc is a leading royalty acquisition company that funds innovation in the biopharmaceutical industry by acquiring existing royalties and co-funding late-stage clinical trials, generating revenue from top-line sales of approved therapies.
- Royalty Pharma has assembled a portfolio of royalties on more than 45 commercial products, including Imbruvica, Xtandi, Tysabri, Trodelvy, Januvia, Promacta, and Vertex's cystic fibrosis franchise [sec · filed 2021-11-10].
- The company reported total revenue of $674.1M and net income of $17.9M for the six months ended June 30, 2026, with cash & equivalents of $812.0M and total debt of $9,341.9M as of that date [sec].
- Royalty Pharma's business model is capital-efficient, benefiting from long product life cycles, significant barriers to entry, and noncyclical revenues, with reduced exposure to early-stage development risk and high R&D costs [sec · filed 2022-05-05].
- The company has historically generated strong operating cash flow, reporting $1.0 billion in net cash provided by operating activities for the six months ended June 30, 2022 [sec · filed 2022-08-04].
What works
- Royalty Pharma's portfolio is diversified across many leading therapies and multiple therapeutic areas, reducing reliance on any single product [sec · filed 2021-11-10].
- The company's business model generates noncyclical revenues with long product life cycles and significant barriers to entry, while avoiding high R&D and manufacturing costs [sec · filed 2022-05-05].
- Royalty Pharma has a track record of generating substantial operating cash flow, with $1.0 billion in net cash provided by operating activities in the first half of 2022 [sec · filed 2022-08-04].
What to weigh
- Royalty Pharma carries a high level of debt, with total debt of $9,341.9M as of June 30, 2026, which could strain liquidity and increase interest expense [sec].
- The company's revenue is dependent on the commercial success of biopharmaceutical products owned by third parties, exposing it to sales risks beyond its control [sec · filed 2022-05-05].
- Royalty Pharma's ability to grow depends on locating and acquiring suitable royalty assets, which may become more competitive or scarce over time [sec · filed 2022-05-05].
From the filings
Quoted directly from source documents.
Royalty Pharma's portfolio includes royalties on more than 45 commercial products.
“We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry's leading therapies, which includes royalties on more than 45 commercial products”
SEC filings · November 10, 2021
The company's business model reduces exposure to common industry challenges.
“Our capital-efficient business model enables us to benefit from many of the most attractive characteristics of the biopharmaceutical industry, including long product life cycles, significant barriers to entry and noncyclical revenues, but with substantially reduced exposure to many common industry challenges such as early stage development risk, therapeutic area constraints, high research and development costs, and high fixed manufacturing and marketing costs.”
SEC filings · May 5, 2022
Catalyst timeline
- 2028-10-12 · Phase3_Topline · apalutamide — A Phase 3, open-label, randomized, prospective study of apalutamide with continued versus intermittent dosing; topline results may influence future royalty payments.
- 2030-03-30 · Phase3_Topline · darolutamide — A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy; positive results could expand royalty potential.
- 2036-07-28 · Patent_Expiry · AMVUTTRA — Patent/exclusivity expiry for AMVUTTRA; loss of exclusivity may reduce royalty income from this product.
- 2040-01-30 · Patent_Expiry · ERLEADA — Patent/exclusivity expiry for ERLEADA; expiration could lead to generic competition and lower royalty receipts.
Risks & what to watch (4)›
Key risks
- High debt level — Total debt of $9,341.9M as of June 30, 2026, which may increase financial risk and interest costs [sec].
- Dependence on third-party product sales — Revenue is tied to sales of biopharmaceutical products owned by others, which may decline or face competition [sec · filed 2022-05-05].
- Asset acquisition uncertainty — Future growth depends on the ability to find and acquire suitable royalty assets at attractive prices [sec · filed 2022-05-05].
- Development-stage product risk — Investments in development-stage candidates may fail to achieve regulatory approval or commercial success [sec · filed 2022-05-05].
What to watch
- Upcoming Phase 3 topline results for apalutamide on October 12, 2028, which could impact royalty revenue if the trial is successful [catalyst].
- Phase 3 topline results for darolutamide on March 30, 2030, representing a potential catalyst for future royalty streams [catalyst].
- Patent expiry for AMVUTTRA on July 28, 2036, which may affect royalty income from that product [catalyst].
- Patent expiry for ERLEADA on January 30, 2040, which could reduce royalty payments from that asset [catalyst].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Royalty Pharma plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Royalty Pharma plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
OCF $728M · Net income $18M · Debt/OCF 2.9×
No tracked pipeline phase
No tracked pipeline candidates
4 upcoming, next in ~774d
0 buys · 21 sells (180d)
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
582
Total value held
$13.50B
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 43,571,633 | $2.09B |
| blackrock, inc. | 25,907,745 | $1.24B |
| fmr llc | 25,152,242 | $1.21B |
| state street corp | 10,989,851 | $527.2M |
| vanguard capital management llc | 9,063,772 | $434.8M |
| geode capital management, llc | 7,869,632 | $376.5M |
| adage capital partners gp, l.l.c. | 7,480,633 | $358.8M |
| caledonia (private) investments pty ltd | 7,168,399 | $343.9M |
| victory capital management inc | 3,853,808 | $184.9M |
| northern trust corp | 3,808,735 | $182.7M |
Showing top 10 of 582 institutional holders of Royalty Pharma plc. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 2.7%
- Days to cover
- 3.3
- Shares short
- 11,520,329
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RPRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Royalty Pharma plc?
Royalty Pharma plc is a leading royalty acquisition company that funds innovation in the biopharmaceutical industry by acquiring existing royalties and co-funding late-stage clinical trials, generating revenue from top-line sales of approved therapies.
What is Royalty Pharma plc's next catalyst?
Royalty Pharma plc's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermitte" — expected October 12, 2028.
Who is the CEO of Royalty Pharma plc?
Mr. Pablo Legorreta is the chief executive officer of Royalty Pharma plc (RPRX).
Where is Royalty Pharma plc headquartered?
Royalty Pharma plc (RPRX) is headquartered in New York, NY, United States.
What therapeutic areas does Royalty Pharma plc focus on?
Royalty Pharma plc develops therapies across Oncology, Neurology, Immunology, Infectious Disease, Metabolic, Dermatology, Nephrology, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.